{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:15:04Z","timestamp":1772781304337,"version":"3.50.1"},"reference-count":36,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,6,4]]},"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Daptomycin, a cyclic lipopeptide that exhibits rapid, concentration-dependent bactericidal activity in vitro against a broad spectrum of Gram-positive pathogens, has now, since 2003, been approved in more than 70 countries and regions to treat skin and soft-tissue infections (SSTIs). The purpose of this meta-analysis was to compare the safety and efficacy of daptomycin with other antibiotics, especially with vancomycin which has long been considered the standard therapy for complicated SSTIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Meta-analysis of randomised controlled trials (RCTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>We thoroughly searched PubMed, EMBASE, Cochrane Central to identify relevant RCTs. Six RCTs with a total of 1710 patients were included in this meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results demonstrated that the efficacy of daptomycin was at par with or maybe better than other first-line antibiotics for treating SSTIs as shown by the OR for clinical success (OR=1.05, 95% CI 0.84 to 1.31, p=0.65, I<jats:sup>2<\/jats:sup>=0%); daptomycin versus vancomycin subgroup (OR=1.19, 95% CI 0.77 to 1.83, p=0.43, I<jats:sup>2<\/jats:sup>=0%); overall microbiological success (OR=1.05, 95% CI 0.61 to 1.79, p=0.86, I<jats:sup>2<\/jats:sup>=42%); microbiological success of daptomycin versus comparators for <jats:italic>Staphylococcus aureus<\/jats:italic> (SA, OR=1.05, 95% CI 0.61 to 2.60, p=0.53, I<jats:sup>2<\/jats:sup>=47%), for methicillin-resistant <jats:italic>S<\/jats:italic>\n                     <jats:italic>. aureus<\/jats:italic> (OR=0.90, 95% CI 0.77 to 1.06, p=0.20, I<jats:sup>2<\/jats:sup>=56%). However, daptomycin tended to have a similar treatment-related adverse events (AEs) incidence in comparison with other antibiotics (OR=1.06, 95% CI 0.71 to 1.59, p=0.76, I<jats:sup>2<\/jats:sup>=41%). The trend showed that daptomycin might cause less discontinuation due to AEs and death compared with other first-line antibiotics (OR=0.71, 95% CI 0.46 to 1.10, p=0.12, I<jats:sup>2<\/jats:sup>=11%). Significantly more patients in the daptomyicn group had creatine phosphokinase elevation than those in the control group; however, it could be reversed when the therapy ended (OR=1.95, 95% CI 1.04 to 3.65, p=0.04, I<jats:sup>2<\/jats:sup>=0).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This meta-analysis demonstrated that the safety and efficacy of daptomycin was not inferior to that of other first-line drugs, and daptomycin tended to exhibit superior efficacy when compared with vancomycin or with comparators for SA infections; nevertheless, more high-quality RCTs are needed to draw a more credible conclusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-004744","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T03:23:23Z","timestamp":1403666603000},"page":"e004744","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"4","author":[{"given":"Shou Zhen","family":"Wang","sequence":"first","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Tao","family":"Hu","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,6,24]]},"reference":[{"key":"2025101812311513000_4.6.e004744.1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1585"},{"key":"2025101812311513000_4.6.e004744.2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363140-00003"},{"key":"2025101812311513000_4.6.e004744.3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq302"},{"key":"2025101812311513000_4.6.e004744.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"2025101812311513000_4.6.e004744.5","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"2025101812311513000_4.6.e004744.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.05.009"},{"key":"2025101812311513000_4.6.e004744.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"2025101812311513000_4.6.e004744.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.028"},{"key":"2025101812311513000_4.6.e004744.9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.4.523"},{"key":"2025101812311513000_4.6.e004744.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"2025101812311513000_4.6.e004744.11","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00002"},{"key":"2025101812311513000_4.6.e004744.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"2025101812311513000_4.6.e004744.13","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"2025101812311513000_4.6.e004744.14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.2.209"},{"key":"2025101812311513000_4.6.e004744.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2948-2953.2000"},{"key":"2025101812311513000_4.6.e004744.16","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2025101812311513000_4.6.e004744.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025101812311513000_4.6.e004744.18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40266-013-0114-8","article-title":"Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial","volume":"30","author":"Konychev","year":"2013","journal-title":"Drugs Aging"},{"key":"2025101812311513000_4.6.e004744.19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","article-title":"Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections","volume":"19","author":"Aikawa","year":"2013","journal-title":"J Infect Chemother"},{"key":"2025101812311513000_4.6.e004744.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.08.007"},{"key":"2025101812311513000_4.6.e004744.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01988.x"},{"key":"2025101812311513000_4.6.e004744.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01854.x"},{"key":"2025101812311513000_4.6.e004744.23","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"2025101812311513000_4.6.e004744.24","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M264"},{"key":"2025101812311513000_4.6.e004744.25","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1611"},{"key":"2025101812311513000_4.6.e004744.26","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"2025101812311513000_4.6.e004744.27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diagmicrobio.2013.07.003","article-title":"Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011)","volume":"77","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025101812311513000_4.6.e004744.28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp704"},{"key":"2025101812311513000_4.6.e004744.29","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31814523f8"},{"key":"2025101812311513000_4.6.e004744.30","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31825d2fa2"},{"key":"2025101812311513000_4.6.e004744.31","doi-asserted-by":"publisher","DOI":"10.1086\/527392"},{"key":"2025101812311513000_4.6.e004744.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.001"},{"key":"2025101812311513000_4.6.e004744.33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijantimicag.2012.12.012","article-title":"Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials","volume":"41","author":"An","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025101812311513000_4.6.e004744.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.12.006"},{"key":"2025101812311513000_4.6.e004744.35","first-page":"447","article-title":"Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin","volume":"5","author":"Stephens","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025101812311513000_4.6.e004744.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00038-12"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-004744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:31:22Z","timestamp":1760815882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-004744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,24]]},"published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1136\/bmjopen-2013-004744"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-004744","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}